natgillin/translations-raw huggingface dataset:
This sample is retained for use in Quality Control release testing. 
Ovaj uzorak je zadržan za uporabu u kontroli kvaliteta.
a transfer, simultaneously from the K levels of the exit elevator to the K levels of the exit transfer device, of said group of N loads; and a transfer of said group of N loads, via the exit sequencer, from the K levels of the exit transfer device to the at least one exit interface conveyor, under a constraint of order of departure of the N loads on said at least one exit interface conveyor. 
– transport (62), istodobno na K razina, navedene skupine od N komada robe od izlaznog dizala do izlaznog transportnog uređaja; i – transport (63) navedene skupine od N komada robe, preko izlaznog sekvencera, od izlaznog transportnog uređaja do najmanje jedne izlazne tekuće vrpce, uz pridržavanje navedenog ograničavanja redoslijeda polaska N komada robe na navedenoj najmanje jednoj izlaznoj tekućoj vrpci.
R8k is halo, C1-4 aliphatic, or C1-4 fluoroaliphatic; and Ring F is an optionally substituted mono-, bi-, or tricyclic ring system, preferably wherein Ring F is an optionally substituted phenyl, napthul, tetrahydronaphthyl, or dihydrobenzofuranyl, or 
k je halogen, C1-4 alifatik ili C1-4 fluoralifatik; i Prsten F je izborno supstituirani mono-, bi- ili triciklični sustav prstena, poželjno pri čemu je prsten F izborno supstituirani fenil, naftil, tetrahidronaftil ili dihidrobenzofuranil, ili
These isoforms vary in their ability to bind IL-18 (Kim et al. 2000). 
Ovi izooblici variraju u svojoj sposobnosti vezanja proteina IL-18 (Kim i sur., 2000).
HL-60 cells were seeded at 6×105 cells/mL in 20 mL RPMI-1640 medium supplemented with 10% fetal bovine serum, 1 mM glutamine and 20 mM gentamycin in a T75 flask and cultured overnight in 5% CO2 atmosphere at 37° C. The cells were treated with 0.1% DMSO or 20 uM of the test compounds (diethyl esters, compounds 1B to 12B and TLK199) in culture medium containing 0.1% DMSO for 2 hours. 
Stanice HL-60 zasijane kod 6x10* stanice/mL u 20 mL RPMI-1640 suplementnog medija sa 10% fetal bovin seruma, ImM glutamina i 20 uM gentamicina u T75 tikvici i kultura se razvijala preko noći u 5% CO2 atmosferi kod 37% €. Stanice su tretirane sa 0.1% DMSO ili 20 uM testnih spojeva (dietil esteri, spojevi 1B do 12B i TLK 199) u mediju kulture koji sadrži 0.1% DMSO 2 sata.
a monoclonal antibody comprising a light chain variable domain containing residues 46-52, 70-72 and 111-116 of SEQ ID NO:2 or SEQ ID NO:6; and 
(i) monoklonalnog antitijela koje sadrži varijabilno područje lakog lanca koje sadrži ostatke 46-52, 70-72 i 111-116 od SEQ ID br. 2;
a bit stream separating step in which the speech decoding device separates a bit stream that includes the encoded speech signal into an encoded bit stream, Spectral Band Replication (SBR) supplementary information and temporal envelope supplementary information, the bit stream received from outside the speech decoding device; 
koraku razdvajanja struje bitova, u kojem naprava za dekodiranje govora razdvaja a struja bitova koja sadrži kodirani govorni signal u kodiranu struju bitova i dodatne informacije o vremenskoj ovojnici, gdje struja bitova dolazi izvan naprave za dekodiranje govora;
it has an amount of G0 structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the protein molecule of said protein molecules in said protein molecule composition which is at least 5% lower compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from ATCC No. 
(iv) ima količinu GO struktura na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli proteina kod navedenih molekula proteina u navedenom pripravku s molekulom proteina koja je najmanje 5% manja u usporedbi s istom količinom molekula proteina u pripravku s najmanje jednom molekulom proteina za istu molekulu proteina koja je izolirana iz ATCC No.
wherein R1 is as defined above, in the presence a heterogeneous acid scavenger. 
Formula V gdje je R1 kako je prethodno definiran, u prisutnosti heterogenog hvatača kiselina.
Number of bonded channels (4 bits) 
(21) Broj predmeta:
3.0-82.0 Total Number of Cycles 
Broj objave europskog patenata:
wherein the weight:weight ratio of the fatty acid ester in the composition to the total active agent in the composition is at least 4:1 fatty acid ester:active agent, and 
% propilen glikola pri čemu je omjer masa: masa estera masne kiseline u pripravku naspram ukupne količine aktivne tvari u spomenutom pripravku barem 4:1 (ester masne kiseline: aktivna tvar), poželjno u rasponu od 4:1 do 20:1.
a protein comprising the amino acid sequence of SEQ ID N°2; 
(A) protein koji ima aminokiselinski slijed SEQ ID NO:2;
insulin glargine or/and a pharmaceutically acceptable salt thereof, and 
(b) inzulin glargina ili/i njegove farmaceutski prihvatljive soli, i
For experimentation, cells were harvested at approximately 80% confluency and plated onto view plates at 40,000 cells per well in 100 µL media and grown overnight. 
Za pokuse, stanice su skupljene kod približno 80%-tne konfluencije i stavljene su u pločice na pločice za gledanje pri koncentraciji od 40.000 stanica po jamici u 100 ul medija i rasle su preko noći.
Glucose isomerase for use according to any one of embodiments 11 to 13 wherein the fructose intolerance is intestinal fructose intolerance; and optionally wherein the intestinal fructose intolerance is caused by a disorder of fructose absorption 
Glukoza izomeraze za uporabu u skladu sa bilo kojim zahtjevom 1 do 3, naznačena time, što intolerancija fruktoze je crijevna intolerancija fruktoze. Glukoza izomeraze za uporabu u skladu sa zahtjevom 4, naznačena time, što crijevna intolerancija fruktoze je uzrokovana poremećajem absorpcije fruktoze.
The stable suspoemulsion of Claim 3 wherein the herbicide is an arylpyridine carboxylic acid or ester of the formula wherein Ar is a polysubstituted phenyl group, R is H or halogen and R1 is H or C1-C8 alkyl. 
Stabilna suspoemulzija u skladu s patentnim zahtjevom 3, naznačena time što je herbicid arilpiridinkarboksilna kiselina, ili njezin ester, formule, gdje je Ar polisupstituirana fenilna skupina, R je H ili halogen, a R1 je H ili C1-C8 alkil.
The method of claim 17, wherein psoriasis is plaque-type psoriasis or refractory psoriasis. 
Spoj za uporabu prema zahtjevu 22, naznačen time da je psorijaza pločasta psorijaza ili refraktorna psorijaza.
calculation by said control unit (260) of the amount of water to be transferred to the liquid spraying components (240) by assessing the data receiving from sensor (261) in accordance with the psychometric diagram, 
- ozračivanje uz pomoć spomenute upravljačke jedinice (260) količine vode koju treba prenijeti na komponente (240) raspršivanja tekućine analizom podataka primljenih od senzora (261) sukladno psihometrijskom dijagramu,
The process according to any one of claims 1 to 10, characterized in that the at least one partially or totally lithium-neutralized water-soluble organic polymer is added before and/or during and/or after step d), if steps e) and f) are not carried out. The process according to any one of claims 1 to 11, characterized in that the at least one partially or totally lithium-neutralized water-soluble organic polymer is added after grinding step d) and before and/or during and/or after screening and/or concentrating step e), if step e) is performed alone. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, karakteriziran na način da je barem jedan djelomično ili potpuno litijem neutraliziran u vodi topljiv organski polimer dodan prije i/ili nakon koraka mljevenja d) i prije i/ili za vrijeme i/ili nakon prosijavanja i/ili ukoncentriravanja u koraku e), ako je korak e) izveden samostalno i/ili je dodan prije i/ili za vrijeme i/ili nakon koraka disperzije f), ako je korak f) proveden.
and wherein the antibody or fragment comprises a variable light chain (VL) in which CDR2 comprises or consists of the amino acid sequence: 
Xje Kili Hili Dili Gili N pri čemu protutijelo ili fragment sadrži varijabilni laki lanac (VL) u kojem CDR2 sadrži ili se sastoji od sekvence amino kiselina:
Alternatively, compounds of formula (I) in which A and X are NH can be prepared by condensing an organometallic reagent ArM onto a compound of formula (VI): 
B, ili - kada A 1 X predstavljaju NH, postupak sadrži korak kondenziranja organometalnog reagensa ArM na spoju formule (VI): posaoaa,
It is preferable to apply the active ingredients simultaneously. 
Poželjno je primjenjivati aktivne sastojke istovremeno.
It is preferred that from 40 to 85 wt %, preferably from 45 to 80 wt %, more preferably from 50 to 75 wt %, most preferably from 60 to 70 wt %, e.g. 65 wt % of the at least one mineral material particles provided in step a) have an equivalent spherical diameter of <10 um, measured by means of a Sedigraph 5100 device from the company Micromeritics, USA, in an aqueous solution of 0.1 wt-% Na4P2O7, wherein the samples were dispersed using a high-speed stirrer and ultrasound. 
Postupak prema bilo kojem od zahtjeva 1 ili 2, naznačen time da od 40 do 85 % tež., poželjno od 45 do 80 % tež., poželjnije od 50 do 75 % tež., najpoželjnije od 60 do 70 % tež., npr. 65 % tež. čestica najmanje jednog mineralnog materijala u koraku a) imaju ekvivalentni sferični promjer od < 10 um.
The use of an acid amide derivative according to claim 13, wherein noxious fungi is Ascomycetes or Deuteromycetes. 
Uporaba derivata amida kiseline u skladu s patentnim zahtjevom 13, naznačen time, da su štetne gljivice Ascomycetes ili Deuteromycetes.
a complementarity determining region light chain 1 (CDRL1) amino acid sequence of SEQ ID NO:46; 
komplementarnu određujuću regiju lakog lanca 1 (CDRL1) aminokiselinsku sekvencu od SEQ ID NO:50;
A non-human animal comprising at endogenous MHC loci: 
Ne-humana životinja, naznačena time, da ona na endogenim MHC (engl.
prior to homogenization at levels greater than 75%; and/or after homogenization at about 50% or at levels greater than 50%; and 
1) prije homogenizacije na razinama većim od 75%; 1/ili 2) nakon homogenizacije na otprilike 50% ili na razinama većim od 50%; i
a measurement unit for being attached to an anchor or an anchor rode (3), the measurement unit comprising: 
(a) mjernu jedinicu koja se pričvršćuje za sidro ili sidreni lanac (3), a koja mjerna jedinica sadrži: i
fermenting a medium containing a source of xylose with a yeast cell as defined in any one of claims 1 to 9, and optionally, recovery of the fermentation product. 
fermentiranje medija koji sadrži izvor ksiloze s stanicom kvasca kako je definiran u bilo kojem od zahtjeva od 1 do 9, i po želji;
In one embodiment, Polymorph A exhibits an X-ray powder diffraction pattern having one or more characteristic peaks expressed in degrees 2-theta at about 3.9+/−0.3 degrees, about 17.5+/−0.3 degrees, and about 22.0+/−0.3 degrees 2-theta. 
Polimorf prema zahtjevu 8, naznačen time da polimorf pokazuje uzorak difrakcije X-zraka na prahu koji ima one ili more karakterističnih vrškova izraženih u stupnjevima 2-theta kod oko 3.9 +/- 0.3 stupnjeva, oko 17.5 +H/- 0.3 stupnjeva, te oko 22.0 +/- 0.3 stupnjeva 2-theta.
A composition for use in the treatment of cancer, comprising an antibody of any one of claims 1-7. 
Izolirano monoklonsko protutijelo za upotrebu za liječenje raka prema zahtjevu 4 naznačeno time da rak sadrži matične stanice raka koje eksprimiraju ABCBS5.
The compound of Claim 1, where R1 is H. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je R1 je H.
The compound of claim 1, or a pharmaceutically acceptable salt, or prodrug thereof for use in the prophylactic or therapeutic treatment of hepatitis C or a hepatitis C associated disorder. 
soli, (2) NS5B polimeraznog inhibitora i (3) NS3 proteaznog inhibitora, za primjenu u profilaktičkom ili terapijskom liječenju hepatitisa C ili poremećaja povezanog sa hepatitisom C. 24.
Component A is a polyfunctional coating resin capable of forming a thermoset either by itself or together with a curing agent, B, upon heat activation. Examples of such resins (component A) are alkyd resins, polyester resins, polyacrylate resins or polymethacrylate resins with either hydroxyl, carboxylic acid or epoxy functional groups suitable for crosslinking reactions. 
Komponenta A je polifunkcionalna smola premaza, koja nakon toplinske aktivacije može tvoriti duromer i to sama ili zajedno sa sredstvom za umreživanje, B. Primjeri takovih smola (komponenta A) jesu alkilne smole, poli-esterske smole, poliakrilatne smole ili polimetakrilatne smole s hidroksilnim skupinama, sa skupinama karboksilne kiseline ili s epoksi funkcionalnim skupinama prikladnim za reakcije umreživanja.
The antisense oligonucleotide as defined in any one of claims 1-14, the vector of claim 15, or the pharmaceutical composition of claim 16, for inducing or promoting exon 45 skipping, optionally in combination with skipping of one of the exons 7, 44, 46, 51, 53, 59, 67, in the dystrophin pre-mRNA for use in treating a DMD or a BMD patient. 
Besmisleni oligonukleotid u skladu s bilo kojim od patentnih zahtjeva 1-14, vektor iz patentnog zahtjeva 15, ili farmaceutski sastav iz patentnog zahtjeva 16, za induciranje ili promoviranje preskakanja eksona 45 za uporabu u liječenju pacijenta s DMD ili BMD.
A process according to claims 1-12 wherein the polymeric shell of the microcapsule is obtainable by reacting the first monomeric component with the second monomeric component by interfacial polymerization by polycondensation or by reacting the second monomeric component formed in situ with the first monomeric component. 
Postupak prema zahtjevima 1-11 naznačen time da polimerna ovojnica mikrokapsule se može dobiti reakcijom prve monomerne komponente s drugom monomernom komponentom interfacijalnom polimerizacijom pomoću polikondenzacije ili reakcijom druge monomerne komponente nastale in situ s prvom monomernom komponentom.
Patents, 13: 499-510 (2003); and D.J. Drucker, "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of Type 2 diabetes," Expert Opin. 
Patents. 13: 499-510 (2003); i DJ. Drucker, "Terapijski potencijal inhibitora dipeptidil peptidaze u liječenju dijabetesa tipa 2" Expert Opin.
After completion of elution, the column was regenerated by rinsing the column with at least 3 BV of purified water. 
Nakon završetka elucije, kolona je bila regenerirana ispiranjem s najmanje 3 BV pročišćene vode.
The invention pertains to a method of contraception, comprising administering to a fertile male, notably human, a compound according to the invention in a dosage amount and regimen, which is sufficient for said compound to be contraceptively effective per se, and which simultaneously serves to maintain a sufficient androgen level in the male subject to this contraceptive method. 
Ovaj izum odnosi se na postupak kontracepcije, koji se sastoji u primjeni na fertilnoj muškoj jedinci, osobito kod ljudi, spoja prema ovom izumu, u količini i režimu doziranja dovoljnom da navedeni spoj bude kao takav djelotvoran kao kontraceptiv, a istodobno služi za održavanje dovoljne razine androgena kod muškarca podvrgnutog ovom postupku kontracepcije.
• removing an aqueous liquid containing polar lipids from the oil-and-water mixture. 
uklanjanja vodene tekućine koja sadrži polarne lipide iz smjese ulje-i-voda.
The method of claim 1, wherein the disease is rheumatoid arthritis. 
Spoj za uporabu prema zahtjevu 11, naznačen time što je bolest reumatoidni artritis.
wherein R8 and R9 may join to form a 5-18 membered mono or bicyclic heterocycle or R8, R9 or R3 may join with R10 to form a 5-7 membered heterocycle, and wherein when X is 4-piparazino, X has the following structure (III): wherein: 
pri čemu R8 i R9 se mogu spojiti da tvore 5-18 člani mono ili biciklički heterocikal ili R8, R9 ili R3 se mogu spojiti s R10 da tvore 5-7 člani heterocikal, i pri čemu kada X je 4-piparazino, X ima sljedeću strukturu (III): pri čemu:
The sheets 6 and 7 are laminated so tightly together that they practically form a uniform part, whereby a counterfeiter is unable to separate the sheets used to produce the data sheet from one another without leaving any traces. 
Listovi 6 i 7 su spojeni zajedno vrlo čvrsto, tako da oni praktički čine jednoličan dio, pri čemu krivotvoritelj ne može rastaviti jedan od drugoga listove koji se koriste za izradu lista za podatke, a da se pri tome ne ostave bilo kakvi tragovi.
isolating precipitated 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride hydrate by solid-liquid separation, preferably filtration, optionally washing with a solvent or a solvent mixture, preferably water, and optionally subsequent drying, preferably in vacuo, optionally at elevated temperature T, preferably 30° C to 95° C, more preferably 70° C. 
izoliranje istaloženog 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoksi)-pirimidin-2-il]-benzil}-6-okso-1,6-dihidro-piridazin-3-il)-benzonitril hidroklorid hidrata uz separaciju kruto-tekuće, poželjno uz filtraciju, proizvoljno uz ispiranje s otapalom ili smjesom otapala, poželjno u vodi, te proizvoljno uz naknadno sušenje, po mogućnosti in vacuo, proizvoljno na povišenoj temperaturi T, poželjno 30° C do 95° C, poželjnije 70° C.
The composition for use according to any of claims 1 to 4, wherein the dose of desmopressin free base is supplied in the form of the acetate salt of desmopressin. 
Pripravak za uporabu prema zahtjevu 1-3, naznačen time da je doza slobodne baze dezmopresina u obliku acetatne soli dezmopresina.
The method according to claim 1, wherein the starting liquid of step a) comprises at least one micro-nutrient and maltose; 
osiguravanje početne tekućine koja sadrži najmanje jednu mikro hranjivu tvar i maltozu, pri čemu je mikro hranjiva tvar odabrana iz skupine koju čine minerali, vitamini, soli i antioksidansi; i
7 and 8 provide similar details concerning the connection of the outputs of the receiver to the joysticks, or equivalent switches, that control the bow and stern thrusters, respectively. 
Slike 7 i 8 prikazuju slične pojedinosti koje se tiču spajanja izlaza prijemnika na palice ili ekvivalentne sklopke, koje upravljaju pramčanim, odnosno krmenim vijcima.
Said text may optically appear in a kind of relief (3D-effect), although the printing itself remains geometrically flat. 
Navedeni tekst može se optički ostvariti u obliku reljefa (3D-učinak), iako samo tiskanje 1 dalje ostaje plošno u geometrijskom smislu.
represents hydrogen; lower alkyl; hydroxycarbonyl-lower alkyl; 1-glyceryl or 2-glyceryl; n represents the integer 0 or 1; and configurational isomers, optically pure enantiomers, mixtures of enantiomers such as racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates and the meso-form, as well as pharmaceutically acceptable salts, solvent complexes, and morphological forms, and inert carrier material. 
R5 predstavlja vodik, niži alkil; hidroksikarbonil-niži alk1l; |-gliceril; ili 2-gliceril; n predstavlja cijeli broj 0 ili L; i konfiguracijske izomere, optički čiste enantiomere, mješavine enantiomera kao što su racemati, diastereomeri, mješavine diastereomera, diastereomerni racemati, mješavine diastereomernih racemata i mezo-oblik, kao i farmaceutski prihvatljive soli, komplekse otapala, i morfološke oblike, te inertne prijenosne materijale; pri čemu izrazi "niži alkil", "niži alkoksi", "mono- ili di-niži alkilamino", 1 "niži alkenil" imaju sljedeća značenja:
the amino acid sequence of residues 25-418 of SEQ ID NO: 12 with a E to S mutation at residue 25; or (iv) the amino acid sequence of residues 25-418 of SEQ ID NO: 12 with a E to S mutation at residue 25 and a C to S mutation at residue 256. 
(iii) aminokiselinsku sekvencu ostataka 25-418 od SEQ ID NO: 12 s mutacijom od E do S na ostatku 25; ili (iv) aminokiselinsku sekvencu ostataka 25-418 od SEQ ID NO: 12 s mutacijom od E do S na ostatku 25 1 s mutacijom od C do S na ostatku 256.
The device according to claim 1, wherein the stretching device comprises a first engaging member (10"; 110a; 210a; 410b) adapted to engage a first part of the stomach wall, and a second engaging member (10"; 110b; 210b; 410b) adapted to engage a second part of the stomach wall close to but spaced from the first stomach part, wherein the operation device is adapted to operate the first and second engaging member to move away from each other, when the engaging members engage the first and second stomach parts, to stretch the stomach wall portion between the first and second parts of the stomach, such that temporary satiety is created. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što uređaj za rastezanje ima prvi međudjelujući element (10"; 110a; 210a; 410b), prilagođen za međudjelovanje s prvim dijelom stijenke želuca, i drugi međudjelujući element (10"; 110b; 2106; 410b), prilagođen za međudjelovanje s drugim dijelom stijenke želuca, blizu, no odvojen od prvog dijela želuca, gdje je uređaj za rukovanje prilagođen za rukovanje prvim i drugim međudjelujućim elementom kako bi ih se razmaknulo jednog od drugog, kada međudjelujući elementi međudjeluju s prvim i drugim dijelom želuca kako bi rastegnuli dio stijenke želuca između prvog i drugog dijela želuca, tako da se postigne privremeni osjećaj sitosti.
A lipid compound according to claim 1, wherein R1 is a C10-C22-alkenyl with 1-6 double bonds. 
Spoj prema zahtjevu 1, naznačen time da R1 je C14-C22 alkenil skupina koja ima prvu dvostruku vezu na trećoj vezi ugljik-ugljik od omega (w) kraja ugljikovog lanca.
A composition comprising a hollow glucan particle or hollow cell wall particle encapsulating a terpene component wherein the lipid content of the hollow glucan particle or hollow cell wall particle is 5% w/w or greater. 
Sastav koji sadrži šuplju glukansku česticu ili česticu šupljih stjenki stanice koja obuhvaća terpenski sastojak gdje terpenski sastojak uključuje mješavinu geraniola, timola i eugenola.
As long as this time period is not expired and/or the thermoblock 10 has not yet reached its operation threshold temperature value, the inlet side will be kept in an evacuation state and the outlet side. 
Ako ovaj vremenski period još nije istekao i/ili termoblok 10 još nije dosegao svoju radnu graničnu vrijednost temperature, izlaznu stranu se drži u stanju pražnjenja, a izlazna strana, tj.
Even more preferably, the process of the invention is such that the gel strengths of adjacent gel masses in the product, at room temperature, when said product is fully jellified, differ by at least 10%, preferably by at least 25%, more preferably by at least 50%. 
Postupak u skladu s patentnim zahtjevima 1 do 3, naznačen time što čvrstoće gela za susjedne mase gela u proizvodu, na sobnoj temperaturi, kada je navedeni proizvod posve želiran, se razlikuju najmanje 10%, po mogućnosti najmanje 25%, poželjnije najmanje 50%.
A compound of formula (X): wherein R' is hydrogen and R is selected from benzyl, acetyl, benzoyl, trifluoromethanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl and benzyloxycarbonyl optionally substituted on the aromatic ring with up to three substituents selected from halogen, cyano and trifluoromethyl; or R' is trimethylsilyl and R is tert-butoxycarbonyl; or R and R' taken together with the nitrogen atom they are linked to form a phthalimido group; and wherein the line means that the double bond of the beta-enaminoketone group can be in cis or trans configuration. 
Postupak iz patentnog zahtjeva 8, naznačen time da je R odabran iz sljedeće skupine: benzil, acetil, benzoil, trifluormethanesulfonil, benzenesulfonil, p-toluensulfonil, metoksikarbonil, etoksikarbonil, ferf-butoksikarbonil, aliloksikarbonil, benziloksikarbonil. HR P20130978 T1 Postupak iz patentnog zahtjeva 7, naznačen time da u spoju formule (VI) R' jest tri(C;-C; alkil)silil, a R jest C;-C alkoksikarbonil ili benziloksikarbonil koji je na aromatskom prstenu supstituiran s do tri supstituenta odbranih od sljedećih: halogen, cijano 1 trifluometilna skupina.